

Calithera Biosciences, Inc.  
Form 4  
August 28, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ADAGE CAPITAL PARTNERS GP LLC

(Last) (First) (Middle)

200 CLARENDON STREET, 52ND FLOOR,

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Calithera Biosciences, Inc. [CALA]

3. Date of Earliest Transaction (Month/Day/Year)  
08/26/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock, par value \$0.0001 ("Common Stock")	08/26/2015		P		200 A \$ 4.7	2,765,875	I See footnote (1)
Common Stock	08/26/2015		P		32,058 A \$ 4.65	2,797,933	I See footnote (1)
Common Stock	08/27/2015		P		9,848 A \$ 5.41	2,807,781	I See footnote (1)

Edgar Filing: Calithera Biosciences, Inc. - Form 4

Common Stock	08/27/2015	P	6,253	A	\$ 5.43	2,814,034	I	See footnote (1)
Common Stock	08/27/2015	P	19,578	A	\$ 5.58	2,833,612	I	See footnote (1)
Common Stock	08/27/2015	P	29,089	A	\$ 5.17	2,862,701	I	See footnote (1)
Common Stock	08/27/2015	P	32,400	A	\$ 5.35	2,895,101	I	See footnote (1)
Common Stock	08/28/2015	P	20,700	A	\$ 5.55	2,915,801	I	See footnote (1)
Common Stock	08/28/2015	P	22,000	A	\$ 5.58	2,937,801	I	See footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 6)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V (A) (D)		

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Reporting Owners

ADAGE CAPITAL PARTNERS GP LLC  
200 CLARENDON STREET, 52ND FLOOR  
BOSTON, MA 02116 X

Adage Capital Partners, L.P.  
200 CLARENDON STREET, 52ND FLOOR  
BOSTON, MA 02116 X

Adage Capital Advisors, L.L.C.  
200 CLARENDON STREET  
52ND FLOOR  
BOSTON, MA 02116 X

Atchinson Robert  
200 CLARENDON STREET  
52ND FLOOR  
BOSTON, MA 02116 X

Gross Phillip  
200 CLARENDON STREET  
52ND FLOOR  
BOSTON, MA 02116 X

## Signatures

/s/ Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson 08/28/2015

\_\_Signature of Reporting Person Date

/s/ Adage Capital Partners, L.P.; By its general partner Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson 08/28/2015

\_\_Signature of Reporting Person Date

/s/ Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson 08/28/2015

\_\_Signature of Reporting Person Date

/s/ Robert Atchinson 08/28/2015

\_\_Signature of Reporting Person Date

/s/ Phillip Gross 08/28/2015

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The securities to which this filing relates are held directly by Adage Capital Partners, L.P., a Delaware limited partnership (the "Fund"). Adage Capital Partners GP, L.L.C., a Delaware limited liability company ("ACPGP"), serves as the general partner of the Fund and as such has discretion over the portfolio securities beneficially owned by the Fund. Adage Capital Advisors, L.L.C., a Delaware limited liability company ("ACA"), is the managing member of ACPGP and directs ACPGP's operations. Robert Atchinson and Phillip Gross are the managing members of ACPGP and ACA and general partners of the Fund. ACPGP, ACA, Robert Atchinson and Phillip Gross disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

## Edgar Filing: Calithera Biosciences, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.